Applications have now closed. All applicants will be advised of the outcome for this grant round in January 2017.

Guide to Applicants

The Hospital Research Foundation (THRF) is proud to announce expressions of interest are now open for our inaugural grant round at the Royal Adelaide Hospital.

Two $250,000 Translational Grants that are ready to commence immediately are available to researchers and clinicians affiliated with the Royal Adelaide Hospital (RAH). Applications will close at 12.00 PM on the 15th December 2017 and short-listed applicants may be required to present more information to THRF’s independent review committee.

About THRF

THRF has been supporting The Queen Elizabeth Hospital and the Basil Hetzel Institute for Translational Health Research for over 50 years and is now proud to extend its support more broadly across South Australia to include the Royal Adelaide Hospital and Centre for Cancer Biology. Our initial support included $1.6million in funding to support the RAH’s own Clinical Trials Centre and $1.1million for world-class cancer research at the Centre for Cancer Biology.

We have also been pleased to support renal research at the RAH, with $1.2million in grants over the past few years and the establishment of our affiliate brand, Kidney, Transplant and Diabetes Research Australia. This includes a recent announcement of $330,000 in funding to ensure six more pancreatic islet auto-transplants can take place at the RAH, saving the lives of people living with severe and hereditary pancreatitis. THRF also proudly supports crucial stroke research at the RAH with the upcoming launch of Cure for Stroke Australia. Both of these affiliate brands will operate out of the RAH.

In October 2017, we opened our own philanthropic hub in the Royal Adelaide Hospital and you can find us on Level 3 (Ground Floor) just opposite the food court. Come and see us to find out more about THRF, its affiliate brands and how we’re committed to helping you save lives and improve care in your hospital!

What is a THRF Translational Grant?

  • THRF’s Translational Grants are designed to support high community impact, “shovel ready” projects at the RAH that have a likelihood of translating into improved therapy, care or cure within three years from the start date
  • Translation is the process of turning observations in the laboratory, clinic and community into interventions that improve the health of individuals and the public — from diagnostics and therapeutics to medical procedures and behavioural changes.

What is the general criteria?

  • Two grants are available of up to $250,000 each
  • Funding will be available immediately
  • There is no specified funding period; the funds will be available immediately and drawdowns will be permitted based on agreed performance milestones being achieved. However translational results should be genuinely expected within three years from the commencement of the funding
  • Up to three Chief Investigators may be listed on an application
  • The CIA must be a clinical researcher at the RAH
  • External (national and international) collaboration is expected
  • THRF encourages collaboration and flexibility exists regarding the % of work to be done at RAH, however there must be a significant RAH research focus to increase the research profile at the hospital and have an impact on patient treatment and care in SA hospitals
  • THRF will fund the RAH Translational grants through Special Purpose Fund accounts at THRF. THRF will enter into a funding agreement with the administering institution.
  • Funds will be released as agreed performance milestones are achieved, and each request will assessed by a THRF Review subcommittee applying quality standards over the research.

What is the assessment criteria?

  • The major criteria on which all expressions of interest/applications will be judged by the Independent Assessment Panel is:
    • Significance/innovation, potential translational impact and outcome (40%)*
    • Scientific excellence (30%)
    • Track record relative to opportunity (30%)* Significance, innovation and outcome, scientific excellence, track record will be assessed using the 7 point category descriptor scale developed by the NHMRC:
      A minimum score of 4 (out of a possible 7) will be required for each of criteria 1,2 and 3 to be eligible for funding. In the event of EOI’s that achieve the same review scores, the ability to attract additional funding from external partners will be allocated bonus scores as follows:

      • Based on a grant from THRF of $250K, leveraged funding of
        • $250k will attract 4 points
        • $187.5k 3 points
        • $125k 2 points
        • $62.5k matched 1 point
        • (Interim sums will be rounded up or down accordingly).

The Panel will provide absolute scores for each application to THRF. An example of a score would be the following:


Assessment Criteria


What are the Terms and Conditions?

  • THRF will provide specific advice on research progress and financial reporting requirements
  • THRF standard Intellectual Property Agreement Clause will apply.
  • Chief Investigators must also agree to:
    • Sign an undertaking to acknowledge THRF funding support in all presentations and papers etc
    • Provide updates upon request about research progress to THRF Communications and Marketing Team
    • Participate in media opportunities coordinated by THRF where necessary, including local radio and local and national media announcements. Relevant media advice and preparation will be available via THRF’s Communications team
    • Ensure THRF is consulted regarding any media opportunities led by the recipient’s University or SA Health
    • Be involved, if requested, in THRF’s Events or Community presentations and laboratory tours, involving presenting to public groups on research in lay terms

How do I apply?

  • Researchers should apply via our online form or complete and submit RAH Translational Grant – EOI Application and send to the email address listed below.
  • If applying via email, applications must be forwarded to CALHN Director of Research, Professor John Beltrame by the very latest at 6.00 am on the 15 December 2017 to ensure they are signed off by the midday deadline. Applications should preferably be submitted earlier in the week since any questions that need to be addressed will have limited time before the close of applications.
  • If applying online, the application will automatically be sent to Prof Beltrame to obtain endorsement. Please submit your application by the very latest at 6.00 am on the 15 December 2017 to ensure it is signed off by the midday deadline.
  • Incomplete applications will not be considered
  • Only ONE application will be considered from each principal researcher as CIA
  • Non-confidential information only is requested
  • Late applications will not be accepted
  • Both manual and digital signatures will be accepted.


All applications are to be submitted electronically no later than 12.00 PM on December 15th 2017 via our website or by completing the RAH Translational Grant – EOI Application and emailing to:

Applications must be endorsed by Prof Beltrame by the very latest at 6.00 AM on the December 15th 2017 to ensure they are signed off by the midday deadline. Applications should preferably be submitted earlier in the week since any questions that need to be addressed will have limited time before the close of applications.

If you are applying via our website, the application will be sent to Prof Beltrame automatically. If you are applying via email, please forward the application to Prof Beltrame (

All queries should be directed to Paul Flynn, THRF CEO at 
8244 1100 or

You can download Guide to Applicants.